NKGen Biotech Presents Novel Manufacturing And Cryopreservation Process For Allogeneic NK Cell Therapy SNK02; CEO Dr. Paul Y. Song Updates On Initial Phase 1 Results For Treating Advanced Refractory Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
NKGen Biotech has presented a novel manufacturing and cryopreservation process for its allogeneic NK cell therapy, SNK02. CEO Dr. Paul Y. Song provided updates on the initial Phase 1 results for treating advanced refractory solid tumors.
June 12, 2024 | 5:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NKGen Biotech has introduced a new manufacturing and cryopreservation process for its NK cell therapy, SNK02, and shared positive initial Phase 1 results for treating advanced refractory solid tumors.
The introduction of a novel manufacturing and cryopreservation process, along with positive initial Phase 1 results, is likely to boost investor confidence and positively impact the stock price of NKGen Biotech in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100